Morepen Laboratories
MOREPENLAB NSE
Morepen Laboratories
HealthcareNSE: MOREPENLAB BSE: 500288 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹6,143 Cr
Volatility
High Risk
P/E Ratio
45.05
EBITDA
₹147 Cr
Return on Equity
7.67%
Debt to Equity
0.17
Book Value
₹22.75
EPS
₹2.15
52W High
₹122.55
52W Low
₹33.05
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
3- Stock is trading at 5.09 times its book value
- The company has delivered a poor sales growth of 8.73% over past five years.
- Company has a low return on equity of 9.26% over last 3 years.
Growth Rate
Revenue Growth
-0.16% lower than
3Y
Net Income Growth
-18.98% lower than
3Y
Cash Flow Change
1.81% higher than
3Y
ROE
-22.84% lower than
3Y
ROCE
-26.33% higher than
3Y
EBITDA Margin (Avg.)
-23.57% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 401 | 422 | 445 | 423 | 455 | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 |
| Expenses | 375 | 388 | 394 | 375 | 404 | 394 | 417 | 424 | 401 | 381 | 438 | 460 | 488 |
| Operating Profit | 26 | 34 | 51 | 48 | 52 | 44 | 36 | 42 | 24 | 31 | 46 | 24 | 83 |
| OPM % | 7% | 8% | 11% | 11% | 11% | 10% | 8% | 9% | 6% | 7% | 10% | 5% | 14% |
| Other Income | 2 | 3 | 4 | 4 | 3 | 5 | 5 | 5 | 4 | 30 | 4 | 8 | 5 |
| Interest | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 5 | 4 | 4 | 4 | 4 | 5 |
| Depreciation | 8 | 8 | 8 | 10 | 6 | 2 | 5 | 16 | 9 | 11 | 10 | 6 | 8 |
| PBT | 21 | 29 | 44 | 42 | 48 | 46 | 35 | 26 | 16 | 46 | 35 | 23 | 75 |
| Tax % | 29% | 26% | 27% | 32% | 25% | 24% | 24% | 21% | 26% | 10% | 22% | 33% | 24% |
| Net Profit | 15 | 21 | 32 | 29 | 36 | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 |
| EPS in Rs | 0.29 | 0.42 | 0.63 | 0.55 | 0.71 | 0.64 | 0.49 | 0.37 | 0.2 | 0.75 | 0.5 | 0.29 | 1.03 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 401 | 485 | 595 | 607 | 769 | 853 | 1,188 | 1,547 | 1,418 | 1,690 | 1,812 | 1,806 | 1,951 |
| Expenses | 352 | 424 | 534 | 542 | 701 | 785 | 1,070 | 1,410 | 1,338 | 1,532 | 1,638 | 1,680 | 1,767 |
| Operating Profit | 48 | 62 | 61 | 65 | 68 | 69 | 119 | 137 | 80 | 159 | 174 | 126 | 184 |
| OPM % | 12% | 13% | 10% | 11% | 9% | 8% | 10% | 9% | 6% | 9% | 10% | 7% | 9% |
| Other Income | 1 | -3 | 4 | 4 | 4 | 9 | 12 | 10 | 6 | 14 | 18 | 47 | 48 |
| Interest | 9 | 10 | 8 | 4 | 2 | 2 | 2 | -7 | 2 | 4 | 8 | 16 | 17 |
| Depreciation | 39 | 35 | 34 | 34 | 40 | 37 | 30 | 28 | 28 | 33 | 29 | 36 | 36 |
| PBT | 2 | 13 | 24 | 30 | 29 | 39 | 99 | 127 | 56 | 135 | 155 | 120 | 179 |
| Tax % | 6% | -1% | 0% | 0% | 1% | 14% | 1% | 20% | 31% | 29% | 24% | 20% | — |
| Net Profit | 2 | 13 | 24 | 30 | 29 | 34 | 97 | 102 | 39 | 97 | 118 | 96 | 141 |
| EPS in Rs | 0.05 | 0.28 | 0.53 | 0.66 | 0.64 | 0.75 | 2.16 | 2.13 | 0.76 | 1.88 | 2.15 | 1.73 | 2.57 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 9% | 12% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 96 | 102 | 102 | 110 | 110 |
| Reserves | 78 | 91 | 106 | 136 | 163 | 194 | 335 | 483 | 651 | 745 | 1,047 | 1,137 |
| Borrowings | 201 | 187 | 169 | 134 | 132 | 133 | 17 | 19 | 25 | 29 | 105 | 208 |
| Other Liabilities | 121 | 156 | 173 | 226 | 230 | 246 | 416 | 473 | 332 | 417 | 517 | 482 |
| Total Liabilities | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,936 |
| Fixed Assets | 322 | 297 | 272 | 264 | 236 | 216 | 225 | 252 | 267 | 307 | 489 | 513 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 14 | 17 | 24 | 28 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 85 | 124 |
| Other Assets | 167 | 227 | 266 | 321 | 379 | 446 | 631 | 804 | 827 | 960 | 1,176 | 1,277 |
| Total Assets | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,936 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 51 | 50 | 41 | 63 | 17 | 11 | 51 | -60 | -91 | 73 | 32 | 33 |
| Investing | -32 | -27 | -14 | -27 | -13 | -12 | -70 | -32 | -47 | -83 | -322 | -126 |
| Financing | -19 | -27 | -24 | -38 | 0 | 5 | 47 | 66 | 144 | 5 | 300 | 97 |
| Net Cash Flow | 0 | -4 | 3 | -1 | 4 | 4 | 28 | -26 | 6 | -5 | 10 | 4 |
| Free Cash Flow | 46 | 41 | 31 | 37 | 6 | -6 | 10 | -127 | -137 | -8 | -182 | -127 |
| CFO/OP | 105 | 81 | 66 | 98 | 26 | 25 | 44 | -26 | -94 | 70 | 40 | 46 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 66 | 57 | 73 | 64 | 59 | 56 | 59 | 68 | 70 | 65 | 67 |
| Inventory Days | 55 | 51 | 65 | 76 | 69 | 91 | 82 | 96 | 87 | 85 | 94 | 88 |
| Days Payable | 126 | 140 | 125 | 173 | 124 | 113 | 98 | 90 | 87 | 101 | 114 | 103 |
| Cash Conversion Cycle | -20 | -23 | -3 | -24 | 9 | 37 | 40 | 65 | 69 | 54 | 45 | 53 |
| Working Capital Days | -20 | -10 | -86 | -62 | -34 | -8 | 17 | 55 | 98 | 94 | 107 | 118 |
| ROCE % | 3% | 8% | 9% | 9% | 8% | 10% | 23% | 23% | 8% | 17% | 15% | 8% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Morepen Laboratories insights
70 extracted metrics + investor summaries across FY06–FY27.
Documents
1
Clarification sought from Morepen Laboratories Ltd
10 Jun - Exchange has sought clarification from Morepen Laboratories Ltd on June 10, 2026, with reference to Movement in Volume. 10 Jun - Exchange has sought clarification from Morepen Laboratories Ltd on June 10, 2026, with reference to Movement in Volume.
2
Compliances-Reg.24(A)-Annual Secretarial Compliance
5h - FY26 secretarial compliance report notes unresolved capital reduction issue for 5,062,872 shares; exchange refused listing alignment. 5h - FY26 secretarial compliance report notes unresolved capital reduction issue for 5,062,872 shares; exchange refused listing alignment.
3
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
6 May - CARE Q4FY26 report shows no deviation; Baddi timeline extended to March 2027; GST SCN Rs117.94 crore disclosed. 6 May - CARE Q4FY26 report shows no deviation; Baddi timeline extended to March 2027; GST SCN Rs117.94 crore disclosed.
4
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
23 Apr - Morepen Laboratories approved ₹30 crore unsecured term loan from Shinhan Bank on April 23, 2026. 23 Apr - Morepen Laboratories approved ₹30 crore unsecured term loan from Shinhan Bank on April 23, 2026.
5
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
11h - Morepen Laboratories approved ₹30 crore unsecured term loan from Shinhan Bank on April 23, 2026. 11h - Morepen Laboratories approved ₹30 crore unsecured term loan from Shinhan Bank on April 23, 2026.
Frequently Asked Questions about Morepen Laboratories
What does Morepen Laboratories Ltd do?
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]
Where is Morepen Laboratories Ltd (MOREPENLAB) listed?
Morepen Laboratories Ltd trades as MOREPENLAB on the NSE and under code 500288 on the BSE.
Which sector does Morepen Laboratories Ltd belong to?
Morepen Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Morepen Laboratories Ltd?
Morepen Laboratories Ltd has a market capitalisation of ₹6,143 Cr, which places it in the Mid Cap band.
What is the PE ratio of Morepen Laboratories Ltd?
Morepen Laboratories Ltd trades at a PE ratio of 45.05, on earnings per share of ₹2.15, against a book value of ₹22.75 per share.
What is the 52-week high and low of Morepen Laboratories Ltd?
Over the last 52 weeks Morepen Laboratories Ltd has traded between ₹33.05 and ₹122.55.
Does Morepen Laboratories Ltd pay dividends?
Morepen Laboratories Ltd has a dividend yield of 0.17%.
What is the Return on Equity (ROE) of Morepen Laboratories Ltd?
Morepen Laboratories Ltd reported a return on equity of 7.67%. Its debt-to-equity ratio is 0.17.
Company Information
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]
Website morepen.com
CEO Mr. Sushil Suri B.Sc., F.C.A.
Employees 1,814
Listed 1999-11-24
Face Value ₹ 2
Issued Size 54,79,53,699
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MOREPENLAB.md for Morepen Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.